Bicara Therapeutics (BCAX) Total Non-Current Liabilities (2023 - 2024)
Bicara Therapeutics' (BCAX) quarterly Total Non-Current Liabilities came in at $18.1 million in Q4 2024, up 17.23% year-on-year from $15.5 million in Q1 2024, and up 23.96% quarter-over-quarter from $14.6 million in Q3 2024.
Bicara Therapeutics (BCAX) Total Non-Current Liabilities (2023 - 2024) Analysis & Trends
Bicara Therapeutics' Total Non-Current Liabilities history runs 2 years deep, the most recent figure standing at $18.1 million for Q4 2024.
- On a quarterly basis, Total Non-Current Liabilities rose 17.23% year-over-year to $18.1 million in Q4 2024; TTM through Dec 2024 was $18.1 million, a 17.23% increase from a year earlier, with the FY2024 full-year figure at $18.1 million, up 17.23% from the prior year.
- Total Non-Current Liabilities grew to $18.1 million in Q4 2024 per BCAX's latest filing, from $14.6 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $18.1 million in Q4 2024 and bottomed at $14.6 million in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.28 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.98 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 949,738.67 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 746.94 Mn |
| 10 | Bicara Therapeutics | 1.68 Bn | 1.68 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 18.12 Mn |
| Sep 30, 2024 | 14.62 Mn |
| Dec 31, 2023 | 15.46 Mn |